Analyst Price Targets — CAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 8:45 am | — | Piper Sandler | $21.00 | $17.89 | TheFly | Caris Life Sciences initiated with a Neutral at Piper Sandler |
| February 17, 2026 10:04 am | — | Robert W. Baird | $26.00 | $20.62 | TheFly | Caris Life Sciences initiated with an Outperform at Baird |
| January 5, 2026 2:46 pm | — | Evercore ISI | $38.00 | $26.68 | TheFly | Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI |
| December 22, 2025 11:52 am | Kyle Mikson | Canaccord Genuity | $30.00 | $27.94 | TheFly | Caris Life Sciences price target raised to $30 from $28 at Canaccord |
| December 2, 2025 10:09 am | — | Canaccord Genuity | $28.00 | $26.05 | TheFly | Caris Life Sciences initiated with a Hold at Canaccord |
| August 13, 2025 11:31 am | Mark Massaro | BTIG | $45.00 | $34.78 | TheFly | Caris Life Sciences price target raised to $45 from $38 at BTIG |
| July 13, 2025 3:03 pm | Subbu Nambi | Guggenheim | $32.00 | $26.51 | TheFly | Caris Life Sciences initiated with a Buy at Guggenheim |
Latest News for CAI
IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance® (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to…
Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwide IRVING, Texas, April 15, 2026 /PRNewswire/ -- Caris Life Sciences® , Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency…
Caris Life Sciences' approach pairs molecular profiling, AI, and large clinico-genomic datasets to support oncology diagnostics, therapy selection, and R&D. Its core platforms are the MI Profile and Caris Assure. These contributed to CAI's strong 2025 revenue growth. CAI clearly benefited from higher reimbursements, better pricing, and rising test volumes in 2025.
Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a groundbreaking AI-driven molecular insight for a subset of mono-immunotherapy eligible non-small cell lung cancer (NSCLC)…
Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight IRVING, Texas, April 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CAI.
U.S. House Trading
No House trades found for CAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.